Analytical methods for analyzing and determining impurities in dianhydrogalactitol

ABSTRACT

An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with evaporative light scattering detection (ELSD); the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.

CROSS-REFERENCES

This application claims the benefit and is a continuation-in-part ofU.S. patent application Ser. No. 13/933,844, by Xiaoyun Lu, entitled“Improved Analytical Methods for Analyzing and Determining Impurities inDianhydrogalactitol,” and filed on Jul. 2, 2013, which in turn claimsthe benefit and is a continuation-in-part of PCT Application Serial No.PCT/IB2013/000793, by Xiaoyun Lu, entitled “Improved Analytical Methodsfor Analyzing and Determining Impurities in Dianhydrogalactitol,” andfiled on Feb. 26, 2013, designating the United States, which in turn,claims the benefit of U.S. Provisional Patent Application Ser. No.61/603,464, entitled “Improved Analytical Methods for Analyzing andDetermining Impurities in Dianhydrogalactitol” by Xiaoyun Lu, filed Feb.27, 2012. The contents of both of these applications are incorporatedherein in their entirety by this reference.

FIELD OF THE INVENTION

This invention is directed to improved analytical methods fordianhydrogalactitol, especially involving high performance liquidchromatography (HPLC).

BACKGROUND OF THE INVENTION

Dianhydrogalactitol (1,2:5,6 dianhydrogalactitol or DAG) is one of anumber of hexitols or hexitol derivatives having significantpharmacological activity, including chemotherapeutic activity. Inparticular, dianhydrogalactitol has been suggested for use inchemotherapy, such as in U.S. Pat. No. 7,157,059 to Nielsen et al.,incorporated herein by this reference.

Dianhydrogalactitol has activity against a number of neoplasms. However,if dianhydrogalactitol is to be used successfully as a therapeuticagent, an extremely high degree of purity and the removal of impuritiesis essential. The presence of impurities can lead to undesirable sideeffects. One example occurred a number of years ago, when impuritiespresent in a batch of the amino acid tryptophan, a normal constituent ofprotein, were responsible for a significant outbreak ofeosinophilia-myalgia syndrome, which caused a large number of cases ofpermanent disability and at least 37 deaths. This is particularlyimportant if the therapeutic agent such as dianhydrogalactitol is to beemployed in patients with compromised immune systems or liver or kidneydysfunction, or in elderly patients. Such patients may experience agreater incidence of undesirable side effects owing to their sensitivityto contaminants.

One of the impurities found in preparations of dianhydrogalactitol isdulcitol. Other impurities exist in preparations of dianhydrogalactitolas well, depending on their method of preparation.

Therefore, there is a need for improved analytical methods to detectimpurities and degradation products in preparations ofdianhydrogalactitol to provide preparations of greater purity that areless likely to induce side effects when dianhydrogalactitol isadministered for therapeutic purposes.

SUMMARY OF THE INVENTION

An improved analytical method for determining the purity ofdianhydrogalactitol and detecting impurities and degradation products inpreparations of dianhydrogalactitol that meets these needs is describedherein.

In general, this analytical method employs high performance liquidchromatography (HPLC), in particular, HPLC with refractive index (RI)detection.

In one alternative, an analytical method for analyzing the presence andquantity of impurities present in a preparation of dianhydrogalactitolcomprises the steps of:

(1) analyzing a preparation of dianhydrogalactitol by subjecting thepreparation to high performance liquid chromatography using elution witha mobile phase gradient to separate dianhydrogalactitol from dulcitoland other contaminants of the preparation; and

(2) determining the relative concentration of one or more peaks resolvedby high performance liquid chromatography that represent compounds otherthan dianhydrogalactitol itself.

The compounds other than dianhydrogalactitol itself can be at least oneof: (1) dulcitol; (2) an impurity other than dulcitol; and (3) adegradation product of dianhydrogalactitol.

In one alternative of this method, elution is with a gradient of NaOHfrom about 2.5 mM to about 0.1 mM. Preferably, elution is with agradient of NaOH from about 1.5 mM to about 0.1 mM. More preferably,elution is with a gradient of NaOH from about 1 mM to about 0.1 mM.

In another alternative of this method, elution is with a gradient of acombination of ammonium hydroxide and a volatile ammonium salt selectedfrom the group consisting of ammonium formate and ammonium acetate andthe total concentration of the ammonium formate and ammonium acetate isfrom about 2.5 mM to about 0.1 mM. Preferably, the total concentrationof the ammonium hydroxide and the volatile ammonium salt selected fromthe group consisting of ammonium formate and ammonium acetate is fromabout 1.5 mM to about 0.1 mM. More preferably, the total concentrationof the ammonium hydroxide and the volatile ammonium salt selected fromthe group consisting of ammonium formate and ammonium acetate is fromabout 1 mM to about 0.1 mM. Typically, the proportion of ammoniumhydroxide and the volatile ammonium salt selected from the groupconsisting of ammonium formate and ammonium acetate is varied from about100:1 at the beginning of elution to about 1:100 at the end of elution.

Typically, in this method, the step of determining the relativeconcentration of one or more peaks resolved by high performance liquidchromatography that represent compounds other than dianhydrogalactitolitself is performed by evaporative light scattering detection.Typically, the evaporative light scattering detection is compatible withelectrospray LC/MS. Typically, the evaporative light scatteringdetection comprises post-column addition of a volatile solvent toenhance evaporation of the 100% aqueous mobile phase. Typically, thevolatile solvent is selected from the group consisting of methanol,ethanol, isopropanol, and acetonitrile.

In one alternative, an electrospray tandem mass spectrometer isinstalled and connected on-line to an HPLC system with ELSD. Typically,in this alternative, mass spectral data providing chemical informationfor each of the impurities that may be present in a preparation ofdianhydrogalactitol is collected. Also, typically, in this alternative,tandem mass spectral data providing structural information for each ofthe impurities that may be present in a preparation ofdianhydrogalactitol is collected.

The method can further comprise the step of performing preparative HPLCcollection of at least one specific substance peak present in apreparation of dianhydrogalactitol. The at last one substance peakpresent in the preparation of dianhydrogalactitol can be an impurity.

In another alternative, instead of gradient elution, isocratic elutioncan be used. When isocratic elution is used, in general, the methodcomprises the steps of:

(1) analyzing a preparation of dianhydrogalactitol by subjecting thepreparation to high performance liquid chromatography using elution withan isocratic mobile phase to separate dianhydrogalactitol from dulcitoland other contaminants of the preparation; and

(2) determining the relative concentration of one or more peaks resolvedby high performance liquid chromatography that represent compounds otherthan dianhydrogalactitol itself.

In one alternative, when isocratic elution is used, the isocratic mobilephase is NaOH, and the concentration of NaOH is from about 5 mM to 0.1mM. Preferably, the concentration of NaOH is from about 2.5 mM to about0.1 mM. More preferably, the concentration of NaOH is about 1 mM.

In another alternative, when isocratic elution is used, the isocraticmobile phase is a combination of ammonium hydroxide and a volatileammonium salt selected from the group consisting of ammonium formate andammonium acetate and the total concentration of the ammonium hydroxideand the volatile ammonium salt selected from the group consisting ofammonium formate and ammonium acetate is from about 5 mM to 0.1 mM.Preferably, the total concentration of the ammonium hydroxide and thevolatile ammonium acetate is from about 2.5 mM to about 0.1 mM. Morepreferably, the total concentration of the ammonium hydroxide and thevolatile ammonium salt selected from the group consisting of ammoniumformate and ammonium acetate is about 1 mM. Typically, the proportion ofammonium hydroxide and the volatile ammonium salt selected from thegroup consisting of ammonium formate and ammonium acetate is about50:50.

Typically, in this alternative, the step of determining the relativeconcentration of one or more peaks resolved by high performance liquidchromatography that represent compounds other than dianhydrogalactitolitself is performed by evaporative light scattering detection (ELSD), asdescribed above. Typically, the evaporative light scattering detectionis compatible with electrospray LC/MS. Typically, the evaporative lightscattering detection comprises post-column addition of a volatilesolvent to enhance evaporation of the 100% aqueous mobile phase.Typically, the volatile solvent is selected from the group consisting ofmethanol, ethanol, isopropanol, and acetonitrile.

In this alternative as well, an electrospray tandem mass spectrometercan be installed and connected on-line to an HPLC system with ELSD.Typically, in this alternative, mass spectral data providing chemicalinformation for each of the impurities that may be present in apreparation of dianhydrogalactitol is collected. Also, typically, inthis alternative, tandem mass spectral data providing structuralinformation for each of the impurities that may be present in apreparation of dianhydrogalactitol is collected.

This alternative of a method according to the present invention canfurther comprise the step of performing HPLC collection of at least onespecific substance peak present in a preparation of dianhydrogalactitol.The at last one substance peak present in the preparation ofdianhydrogalactitol can be an impurity.

In still another alternative, an analytical method for analyzing thepresence and quantity of impurities present in a preparation ofdianhydrogalactitol comprises the step of analyzing a preparation ofdianhydrogalactitol by subjecting the preparation to high performanceliquid chromatography (HPLC) on an HPLC column using elution with amobile phase gradient to separate dianhydrogalactitol from dulcitol andother contaminants of the preparation; wherein the high performanceliquid chromatography employs evaporative light scattering detection(ELSD).

Typically, the HPLC column is a silica gel column bonded to C18compounds and finished with an endcapping procedure employing Lewisacid-Lewis base chemistry.

Typically, elution is performed with a gradient of 95% water/5%acetonitrile to 70% water/30% acetonitrile, returning to 95% water/5%acetonitrile. Typically, the time schedule for varying the eluant is asfollows: 0 minutes, 95% water/5% acetonitrile; 15 minutes, 95% water/5%acetonitrile; 15.1 minutes, 70% water/30% acetonitrile; 20 minutes, 70%water/30% acetonitrile; 20.1 to 35 minutes, 95% water/5% acetonitrile.Typically, the method detects a monoepoxide degradation product ofdianhydrogalactitol, a monoepoxide dimer, and dulcitol. Preferably, themethod also detects a dimer of dianhydrogalactitol and condensedproducts.

Typically, the peaks resulting from HPLC are analyzed by LC-MS.

Typically, the method further comprises a step of determining therelative concentration of one or more peaks resolved by high performanceliquid chromatography that represent compounds other thandianhydrogalactitol itself.

In an alternative for detection by ELSD, typically, the columntemperature is about 30° C.

Typically, the flow rate is about 0.5 mL/min. Typically, the ELSDdetector is operated in cooling mode with the drift tube temperature of35° C. and gain 400, 2 pps, 45 PSI. Typically, in this alternative,Mobile Phase A and Mobile Phase B are employed, with Mobile Phase Abeing 0.05% formic acid in water and Mobile Phase B being 100% methanol.Typically, with these mobile phases, elution is performed from 0 minutesto 25 minutes with 100% of 0.05% formic acid in water, from 25 minutesto 25.1 minutes with 90% of 0.05% formic acid in water and 10% of 100%methanol, from 25.1 minutes to 35 minutes with 10% of 0.05% formic acidin water and 90% of 100% methanol, and from 35.1 minutes to 50 minuteswith 100% of 0.05% formic acid in water.

The method can further comprise the preparation of an externalcalibration standard curve for an impurity. The impurity can be selectedfrom the group consisting of dulcitol, a monoepoxide degradation productof dianhydrogalactitol, and a dimer of dianhydrogalactitol. The methodcan estimate the content of an unknown impurity by using a calibrationstandard curve established by chromatography of dianhydrogalactitolreference material.

Another alternative employing HPLC and ELSD employs a dual elutionsequence. The dual elution sequence is as follows: a first part of theelution sequence in which elution is performed from 0 minutes to 25minutes with 100% of 0.05% formic acid in water, from 25 minutes to 25.1minutes with 90% of 0.05% formic acid in water and 10% of 100% methanol,from 25.1 minutes to 35 minutes with 10% of 0.05% formic acid in waterand 90% of methanol, and from 35.1 minutes to 50 minutes with 100% of0.05% formic acid in water, and a second part of the elution sequence inwhich elution is performed as follows: from 0 minutes to 7.5 minuteswith 100% of 0.05% formic acid; from 7.5 minutes to 7.6 minutes with 97%of 0.05% formic acid and 3% of methanol; and from 7.6 minutes to 20minutes with 100% of 0.05% formic acid. In this alternative, typicallythe column temperature for HPLC is about 30° C., the sample temperaturefor HPLC is about 5° C., the flow rate for HPLC is about 0.5 mL/min, andthe injection volume is about 10-100 μL. In this alternative, typically,for ELSD, the gain is about 400, the drift tube temperature is about 45°C., the gas pressure is about 35 PSI of nitrogen, the nebulizer is setto cooling, the data rate is 2 points per second, and the Rayleighfactor is about 6.0. Typically, in this alternative, standards ofdulcitol at 0.1, 0.08, 0.05, 0.03, 0.01, 0.005 mg/mL are employed todetermine the sensitivity and linearity of the system. Typically, inthis alternative, the retention time for dulcitol is about 6.4 minutesand the retention time for dianhydrogalactitol is about 12.1 minutes. Inthis alternative, the amount and percentage of a dulcitol impurity canbe determined from the results of HPLC and ELSD. Also, in thisalternative, the amount and percentage of an unknown impurity other thandulcitol can be determined from the results of HPLC and ELSD.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the presentinvention will become better understood with reference to the followingdescription, appended claims, and accompanying drawings where:

FIG. 1 is a representative HPLC/RI chromatogram of a preparation ofdianhydrogalactitol, showing resolution of dulcitol and an unknownrelated substance at RRT˜0.6 in the bulk drug and drug product.

FIG. 2 shows representative HPLC chromatograms showing resolution ofdianhydrogalactitol and dulcitol in a standard, and, for comparison, awater blank; in FIG. 2, the dianhydrogalactitol-dulcitol standard isshown in the top panel, and the water blank is shown in the bottompanel.

FIG. 3 is a HPLC chromatogram of a dianhydrogalactitol clinical sampleusing an evaporative light scattering detector for detection showing theexistence of a possible dianhydrogalactitol dimer and possible condensedproducts, along with the monoepoxide and dulcitol as degradationproducts.

FIG. 4 is a mass spectroscopy profile of the impurity peak occurring at22.6 minutes of the HPLC chromatogram of FIG. 3.

FIG. 5 is a chromatogram of a sample of dianhydrogalactitol as performedin Example 3 employing 0.05% formic acid in water as Mobile Phase A and100% methanol as Mobile Phase B.

FIG. 6 is an example chromatogram of a blank solution as performed inExample 4.

FIG. 7 is an example chromatogram of an 0.10% dulcitol solution asperformed in Example 4.

FIG. 8 is an example chromatogram of a test solution as performed inExample 4.

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to improved analytical methods fordetermining the purity of dianhydrogalactitol and determining theexistence and concentration of impurities present in preparations ofdianhydrogalactitol.

The structure of dianhydrogalactitol is shown below in Formula (I).

One of the significant impurities present in dianhydrogalactitolpreparations is dulcitol. The structure of dulcitol is shown below inFormula (II). Other impurities are known to exist in dianhydrogalactitolpreparations.

An improved method of analyzing dianhydrogalactitol preparations isbased on HPLC (high performance liquid chromatography) with evaporativelight scattering detection (ELSD). In one alternative, to detect andidentify all significant components present in such dianhydrogalactitolpreparations, HPLC is combined with mass spectroscopy (MS).

The theory and practice of HPLC are described in L. R. Snyder et al.,“Introduction to Modern Liquid Chromatography” (3^(rd) ed., John Wiley &Sons, New York, 2009). The theory and practice of MS are described in E.de Hoffmann & V. Stroobant, “Mass Spectroscopy: Principles andApplications” (3^(rd) ed., John Wiley & Sons, New York, 2007).

The HPLC method has demonstrated resolution of a synthetic intermediate,dulcitol, in preparations of dianhydrogalactitol, in addition toresolution of an unknown related substance observed at RRT 0.6 (FIG. 1).FIG. 1 is a representative HPLC/RI chromatogram of a preparation ofdianhydrogalactitol, showing resolution of dulcitol and an unknownrelated substance at RRT˜0.6 in the bulk drug and drug product.Representative HLPC chromatograms showing resolution ofdianhydrogalactitol and dulcitol in a standard, and, for comparison, awater blank, are shown in FIG. 2. In FIG. 2, thedianhydrogalactitol-dulcitol standard is shown in the top panel, and thewater blank is shown in the bottom panel.

The present application describes improved HPLC chromatographicconditions for resolution of potentially co-eluting substances. Athermally stressed dianhydrogalactitol product sample is evaluated toprovide confirmation of the chromatographic conditions appropriate forresolution of dulcitol and other related impurities and degradationproducts. Subsequently, LC/MS and LC/MS/MS is performed to characterizethe unknown DAG-related substance at RRT˜0.6 to provide mass spectralcharacterization and determination of the chemical structure of thisunidentified component.

Previously employed HPLC conditions involve isocratic elution ofdianhydrogalactitol and its related substances using a 50 mM NaOH mobilephase. In an improvement on these conditions, employed as part of themethod disclosed herein, a gradient mobile phase is employed. Onealternative is the use of NaOH in a concentration gradient. If NaOH isemployed in a concentration gradient, typically elution is with agradient of NaOH from about 2.5 mM to about 0.1 mM. Preferably, elutionis with a gradient of NaOH from about 1.5 mM to about 0.1 mM. Morepreferably, elution is with a gradient of NaOH from about 1 mM to about0.1 mM.

In another alternative, a combination of ammonium hydroxide and avolatile ammonium salt selected from the group consisting of ammoniumformate and ammonium acetate can be used as eluant. In this alternative,the total concentration of the ammonium formate and ammonium acetate isfrom about 2.5 mM to about 0.1 mM. Preferably, the total concentrationof the ammonium hydroxide and the volatile ammonium salt selected fromthe group consisting of ammonium formate and ammonium acetate is fromabout 1.5 mM to about 0.1 mM. More preferably, the total concentrationof the ammonium hydroxide and the volatile ammonium salt selected fromthe group consisting of ammonium formate and ammonium acetate is fromabout 1 mM to about 0.1 mM. Typically, the proportion of ammoniumhydroxide and the volatile ammonium salt selected from the groupconsisting of ammonium formate and ammonium acetate is varied from about100:1 at the beginning of elution to about 1:100 at the end of elution.

Other gradient elution schemes are known in the art.

Typically, in HPLC analytical methods according to the presentinvention, detection is by means of evaporative light scattering (ELSD).An evaporative light scattering detector (ELSD) atomizes the columneluate, shines light on the resulting particulate components, anddetects the resulting scattered light. Theoretically, an ELSD can detectany nonvolatile component. The evaporative light scattering detection ofa non-chromogenic compound is based on nebulization of the HPLC eluantand evaporation of mobile-phase solvents to produce atomizing soluteparticles for light scattering detection. This nebulization and solventevaporation process to produce atomizing analyte solute particles iscomparable to the electrospray LC/MS procedure. Typically, the ELSDdetection is compatible with electrospray LC/MS.

Implementation of an HPC method with ELSD detection that is compatiblewith electrospray LC/MS application involves post-column addition of avolatile solvent to enhance evaporation of the 100% aqueous mobilephase. The volatile solvent is typically selected from the groupconsisting of methanol, ethanol, isopropanol, and acetonitrile.

Accordingly, in methods according to the present invention, anelectrospray tandem mass spectrometer is installed and connected on-lineto an HPLC system with ELSD. Mass spectral data providing molecularinformation and tandem mass spectral data providing chemical structuralinformation for each of the impurities that may be present in apreparation of dianhydrogalactitol can be collected. Mass spectroscopyin tandem with HPLC will provide molecular ion information and possiblechemical structures having a molecular weight consistent with themolecular ion information for each of the observed impurities anddegradation products.

In another alternative, preparative HPLC collection of specificDAG-related substance peaks, including impurities present in apreparation of DAG, can be performed.

Accordingly, one analytical method for analyzing the presence andquantity of impurities present in a preparation of dianhydrogalactitolcomprises the steps of:

(1) analyzing a preparation of dianhydrogalactitol by subjecting thepreparation to high performance liquid chromatography using elution witha mobile phase gradient to separate dianhydrogalactitol from dulcitoland other contaminants of the preparation; and

(2) determining the relative concentration of one or more peaks resolvedby high performance liquid chromatography that represent compounds otherthan dianhydrogalactitol itself.

The compounds other than dianhydrogalactitol itself can be at least oneof: (1) dulcitol; (2) an impurity other than dulcitol; and (3) adegradation product of dianhydrogalactitol.

Typically, in one alternative, in this method, the mobile phase gradientis a gradient of sodium hydroxide.

In another alternative, in this method, the mobile phase gradient is agradient of a combination of ammonium hydroxide and a volatile ammoniumsalt selected from the group consisting of ammonium formate and ammoniumacetate.

Typically, in this method, detection is by evaporative light scattering.Typically, when evaporative light scattering is employed, the methodfurther comprises the step of post-column addition of a volatile solventto enhance evaporation of components of the mobile phase.

Typically, the present invention further comprises the step of analyzingone or more peaks eluting from the high performance liquidchromatography by electrospray tandem mass spectroscopy.

In one alternative, the present invention further comprises the step ofpreparative HPLC collection of at least one specific DAG-relatedsubstance peak.

If an impurity or degradation product (other than dulcitol) exists, theunknown impurity or degradation product can be identified by separationby column chromatography followed by at least one purification procedureto yield a solid unknown sample which can then be characterized foridentification by at least one standard analytical procedure selectedfrom the group consisting of nuclear magnetic resonance (NMR), massspectroscopy (MS), Fourier transform infrared spectroscopy (FT-IR),elemental analysis, determination of purity by HPLC, and determinationof water content by the Karl Fischer titration method. These methods arewell known in the art.

In another alternative, the method comprises:

(1) analyzing a preparation of dianhydrogalactitol by subjecting thepreparation to high performance liquid chromatography using elution withan isocratic mobile phase to separate dianhydrogalactitol from dulcitoland other contaminants of the preparation; and

(2) determining the relative concentration of one or more peaks resolvedby high performance liquid chromatography that represent compounds otherthan dianhydrogalactitol itself.

As in the method employing gradient elution, the compounds other thandianhydrogalactitol itself can be at least one of: (1) dulcitol; (2) animpurity other than dulcitol; and (3) a degradation product ofdianhydrogalactitol.

In this alternative, the elution with the isocratic mobile phase caneither be elution with sodium hydroxide or elution with a combination ofammonium hydroxide and a volatile ammonium salt selected from the groupconsisting of ammonium formate and ammonium acetate. If the isocraticmobile phase is sodium hydroxide, typically, the concentration of NaOHis from about 5 mM to 0.1 mM. Preferably, the concentration of NaOH isfrom about 2.5 mM to about 0.1 mM. More preferably, the concentration ofNaOH is about 1 mM. If the isocratic mobile phase is a combination ofammonium hydroxide and a volatile ammonium salt selected from the groupconsisting of ammonium formate and ammonium acetate, the totalconcentration of the ammonium hydroxide and the volatile ammonium saltselected from the group consisting of ammonium formate and ammoniumacetate is from about 5 mM to 0.1 mM. Preferably, the totalconcentration of the ammonium hydroxide and the volatile ammoniumacetate is from about 2.5 mM to about 0.1 mM. More preferably, the totalconcentration of the ammonium hydroxide and the volatile ammonium saltselected from the group consisting of ammonium formate and ammoniumacetate is about 1 mM. Typically, the proportion of ammonium hydroxideand the volatile ammonium salt selected from the group consisting ofammonium formate and ammonium acetate is about 50:50.

In an alternative method to improve resolution, an evaporative lightscattering detector (ELSD) is employed employing altered elutionconditions. Typically, in this method, the HPLC column is a silica gelcolumn bonded to C18 compounds and finished with an endcapping procedureemploying Lewis acid-Lewis base chemistry such as the YMC C18 column.Typically, elution is performed with a gradient of 95% water/5%acetonitrile to 70% water/30% acetonitrile, returning to 95% water/5%acetonitrile. Preferably, the time schedule for varying the eluant is asfollows: 0 minutes, 95% water/5% acetonitrile; 15 minutes, 95% water/5%acetonitrile; 15.1 minutes, 70% water/30% acetonitrile; 20 minutes, 70%water/30% acetonitrile; 20.1 to 35 minutes, 95% water/5% acetonitrile.Preferably, the HPLC method detects a monoepoxide degradation product ofdianhydrogalactitol, a monoepoxide dimer, and dulcitol. More preferably,the HPLC method also detects a dimer of dianhydrogalactitol andcondensed products.

Preferably, in this alternative of the method, the peaks resulting fromHPLC are analyzed by LC-MS.

In another alternative method, as shown in Example 3, an Atlantis HPLCcolumn is employed. Typically, in this method, the column temperature isabout 30° C. Typically, in this method, the flow rate is about 0.5mL/min. Typically, in this method, the injection volume is about 10 μLto about 100 μL. Typically, in this method, an ELSD detector is used.Typically, in this method, the ELSD detector is operated in cooling modewith the drift tube temperature of 35° C. and gain 400, 2 pps, 45 PSI.Typically, in this method, Mobile Phase A and Mobile Phase B areemployed, with Mobile Phase A being 0.05% formic acid in water andMobile Phase B being 100% methanol. Typically, in this method, elutionis performed from 0 minutes to 25 minutes with 100% of 0.05% formic acidin water, from 25 minutes to 25.1 minutes with 90% of 0.05% formic acidin water and 10% of 100% methanol, from 25.1 minutes to 35 minutes with10% of 0.05% formic acid in water and 90% of 100% methanol, and from35.1 minutes to 50 minutes with 100% of 0.05% formic acid in water.

Typically, this alternative of the method further comprises thepreparation of an external calibration standard curve for an impurity.The impurity can be, but is not limited to, an impurity selected fromthe group consisting of dulcitol, a monoepoxide degradation product ofdianhydrogalactitol, and a dimer of dianhydrogalactitol. In this method,for an unknown impurity, the content of the unknown impurity can beestimated using a calibration standard curve established bychromatography of dianhydrogalactitol reference material.

In another alternative, as shown in Example 4, following the elutionsequence described above, namely where elution is performed from 0minutes to 25 minutes with 100% of 0.05% formic acid in water, from 25minutes to 25.1 minutes with 90% of 0.05% formic acid in water and 10%of 100% methanol, from 25.1 minutes to 35 minutes with 10% of 0.05%formic acid in water and 90% of 100% methanol, and from 35.1 minutes to50 minutes with 100% of 0.05% formic acid in water, an additionalelution sequence is performed as follows: from 0 minutes to 7.5 minuteswith 100% of 0.05% formic acid; from 7.5 minutes to 7.6 minutes with 97%of 0.05% formic acid and 3% of methanol; and from 7.6 minutes to 20minutes with 100% of 0.05% formic acid. In this alternative, typicallythe column temperature for HPLC is about 30° C., the sample temperaturefor HPLC is about 5° C., the flow rate for HPLC is about 0.5 mL/min, andthe injection volume is about 100 μL. In this alternative, typically,for ELSD, the gain is about 400, the drift tube temperature is about 45°C., the gas pressure is about 35 PSI of nitrogen, the nebulizer is setto cooling, the data rate is 2 points per second, and the Rayleighfactor is about 6.0. Typically, in this alternative, standards ofdulcitol at 0.005 to 0.1 mg/mL are employed to determine the sensitivityand linearity of the system. Typically, in this alternative, theretention time for dulcitol is about 6.4 minutes and the retention timefor dianhydrogalactitol is about 12.1 minutes. In this alternative, theamount and percentage of a dulcitol impurity can be determined from theresults of HPLC and ELSD. Also, in this alternative, the amount andpercentage of an unknown impurity other than dulcitol can be determinedfrom the results of HPLC and ELSD.

The invention is illustrated by the following Examples. These examplesare for illustrative purposes only, and are not intended to limit theinvention.

EXAMPLES Example 1 HPLC Analysis of Dianhydrogalactitol PreparationsEmploying Isocratic Sodium Hydroxide Elution

The procedure described in this Example is used for determining dulcitoland related impurities in a dianhydrogalactitol drug preparation by ionexchange high performance liquid chromatography with refractive indexdetection.

In this procedure, the samples are prepared with dianhydrogalactitol ata target concentration of 5 mg/mL. Dulcitol, dianhydrogalactitol, andrelated impurities are separated using an anion exchange column(Hamilton RCX-10, 250×4.1 mm, 7 μm), with 50 mM NaOH as isocratic mobilephase with refractive index detection. Dulcitol concentration isdetermined with an external reference standard and the contents ofrelated substances are estimated using a DAG reference standard.

A suitable HPLC system and data acquisition system is an AgilentTechnologies 1200 Series HPLC system or equivalent equipped with thefollowing: Quat pump, Model G1311A or equivalent; auto sampler, Model1329A or equivalent; RID detector, Model 1362A or equivalent; columntemperature controller capable of 30±3° C.; and degasser, Model G1322 orequivalent. The column is a Hamilton RCX anion exchange column250×4.1-mm, 7 μm, P/N 79440, or equivalent. Data acquisition isperformed by a ChemStation and ChemStore Client/Server or an equivalentdata system.

The following chemicals are used. Water is Milli-Q water or deionizedwater. Sodium hydroxide is standard purified grade. Dulcitol and DAGreference standards are of purity >98.0%.

For the mobile phase (50 mM NaOH), 2.0 g NaOH is dissolved in 1 liter ofwater. The solution is filtered through an 0.45-μm filter. The mobilephase can be stored up to 1 month at room temperature. For the dulcitolreference stock solution (nominal 500 μg/mL), 25 mg of dulcitolreference standard is accurately weighed into a 50-mL volumetric flask.The dulcitol is diluted to volume with deionized water and mixed well.The prepared stock solution can be stored up to 3 days at 2-8° C. Forthe DAG reference stock solution (nominal 500 μg/mL), 25 mg of DAGreference standard is accurately weighed into a 50-mL volumetric flask.The DAG is diluted to volume with deionized water and mixed well. Theprepared stock solution can be stored up to 3 days at 2-8° C. For thedulcitol-DAG standard solution (dulcitol 50 μg/mL+DAG 50 μg/mL; each at1% of 5 mg/mL DAG), 1.0 ml of dulcitol stock and 1.0 ml of DAG stock areeach quantitatively transferred into a 10-mL volumetric flask, dilutedto volume with water and mixed well.

For DAG sample preparation from an API sample (nominal 1 mg/mL), about25 mg of API sample of DAG is accurately weighed in a clean 25-mLvolumetric flask. The DAG API sample is dissolved in approximately 5 mLof deionized water, diluted to volume with deionized water, and mixed.An aliquot of 1 to 2 mL of the test sample is transferred into an HPLCvial. Prepared samples can be stored for up to 2 days at 2-8° C.

For DAG sample preparation (nominal 5 mg/mL) for an API sample, about 50mg of the API sample is accurately weighed into a clean 10-mL volumetricflask. The DAG API sample is dissolved in approximately 5 mL of water,diluted to volume with water, and mixed.

For DAG sample preparation from a lyophilized (40 mg/vial) sample, thesample is removed from the refrigerator in which the sample is storedand the seal removed. A volume of water of 5.0 mL is quantitativelytransferred and the solution is mixed to dissolve the DAG, yielding an 8mg/mL solution. An aliquot of 1.0 g of the reconstituted solution isdiluted to 8.0 g with deionized water and mixed. A further aliquot of 1to 2 mL of the test sample is transferred into an HPLC vial. Preparedsamples can be stored for up to 2 days at 2-8° C.

For DAG sample preparation (nominal 5 mg/mL) for the drug product usinglyophilized powder (40 mg/vial), the closure of the vial is cleaned andremoved. The lyophilized vial is reconstituted with 8.0 mL water toyield a 5 mg/mL solution. An aliquot of 1 to 2 mL is transferred to anHPLC vial. Samples are prepared in duplicate (using two vials). Preparedsamples can be stored at 2-8° C. for up to 24 hours.

For HPLC analysis, the HPLC system is turned on and the detector isallowed to warm up for at least 20 minutes. If necessary, place the HPLCmobile phase prepared as described above into the appropriate solventinlet. The solvent line is primed with the mobile phase. The system andthe column are equilibrated with HPLC mobile phase at a flow rate of 1.5mL/min for at least 30 minutes. A sample analysis sequence is created.Once system suitability has been confirmed, a water blank is injectedfollowed by injections of the standards and then the samples. Adulcitol-DAG standard is inserted after every 10 injections of samplesand then a last bracketing standard at the end of the run. A suitablesample analysis sequence is shown in Table

TABLE 1 Sample Analysis Sequence No. of Description Injections Blank(100% water) 1 System Suitability Test, Dul-DAG Standard (50 μg/mL each)6 Blank (100% water) 1 Test Samples (DAG drug substance and/or drug 2product) - assay (duplicate preparations) (n ≦ 20) Bracketing Standard,Dul-DAG Standard (50 μg/mL each) 2 Blank (water) 1

The samples are analyzed using RID. As indicated above, a suitablecolumn is a Hamilton RCX ion exchange column (250×4.1 mm, 7 μm), P/N79440 or equivalent. The mobile phase is 50 mM NaOH in deionized water(isocratic elution). The flow rate is 1.5 mL/min. The column temperatureis 30° C. The injection volume is 50 μL. Detection is by RID at 35° C.The run time is 8 minutes.

For analysis and integration of the chromatograms, the HPLC software isused. The chromatograms for the blank, the samples, and the teststandards are reviewed and compared. Manual integration and assignmentof some peaks may be necessary. Integration parameters such as slopesensitivity, peak width, peak height threshold value for rejection,integration type of shoulder peak, baseline, and split peak, as well asother parameters, are adjusted to obtain appropriate integration andvalues for these parameters are recorded and applied to all samples andstandards.

Suitability of the system is assessed as follows. The six replicatedinjections of the dulcitol-DAG standard solution are evaluated using thechromatographic performance requirements of Table 2.

TABLE 2 Chromatographic Performance Requirements Dulcitol Retention time(RT): ~2 min. DAG Retention time (RT): ~6 min. Area Response variation %RSD: ≦10.0% Retention time variation % RSD: ≦2.0%

The dulcitol and DAG peak area in the bracketing standard solutioninjections should be 80% to 120% of the average peak area of each inprevious SST injections. In case one bracketing standard fails to meetthe criterion, the samples analyzed after the final passing bracketingstandard should be re-analyzed.

In the analysis of the data, relative peak area=(peak area/total peakarea)×100, where “peak area” is the individual peak area and “total peakarea” is the sum of peak areas from all peaks.

Dulcitol concentration is calculated as indicated: Dulcitol (Cu,μg/mL)=Cs×mean sample peak area/mean dulcitol peak area of Dul-DAGstandard injections, where Cs is dulcitol concentration in μg/mL.

Dulcitol content (wt %) in DAG drug substance or drug product iscalculated as indicated: Dulcitol wt %=Cu (μg/mL)/1000/SC (mg/mL)×100%,where Cu is dulcitol concentration (μg/mL) calculated as above, and SCis sample concentration (mg/mL) as prepared for drug substance or drugproduct. If dulcitol is present, the weight percent of dulcitol isreported if equal to or greater than 0.05%; it is reported to thenearest 0.01%.

If an unknown or previously unidentified impurity other than dulcitol ispresent in the DAG preparation, its concentration is calculated asfollows: Unknown impurity concentration (μg/mL)=Cs×mean sample peakarea/mean DAG peak area of Dul-DAG standard injections. If present, theunknown impurity weight percent is calculated as follows: Cu(μg/mL)/1000/SC (mg/mL)×100%, where Cu=unknown concentration (μg/mL)calculated as above, and SC=sample concentration (mg/mL) as prepared in[0077] for drug substance or [0079] for drug product. Each unknownimpurity, if present, is reported if equal to or greater than 0.05%; itis reported to the nearest 0.01%.

The assay results in weight percent are calculated for each sample andfor the mean of duplicate samples.

Example 2 HPLC Analysis Employing Evaporative Light Scattering DetectorUsing Gradient of Water/Acetonitrile

To improve resolution of impurities, another method of HPLC analysis wasemployed using an evaporative light scattering detector (ELSD) with agradient of water/acetonitrile as detailed below.

Due to the limitations of the refractive index (RI) detector, theHPLC/RI method does not have sufficient specificity to obtain reliableimpurity profile data, which pose the risks of exposure of patients tounacceptable levels of impurities that are unknown or are incompletelycharacterized. To address this concern, a more sensitive detector, suchas the evaporative light scattering detector (ELSD) manufactured byAgilent, is used in conjunction with HPLC system for determination ofimpurities found in dianhydrogalactitol drug substance or drug product.

For example, a DAG sample was analyzed by HPLC/ELSD method using a YMCC18 column with the gradient shown in Table 3:

TABLE 3 Time (min) % water % acetonitrile 0 95 5 15 95 5 15.1 70 30 2070 30 20.1 to 35 95 5

As shown in the chromatogram (FIG. 3), dulcitol was eluted at retentiontime of 4.5 minutes. The peaks eluted right after dulcitol wereidentified to be mono-epoxide related compounds, as supported by LC-MSdata summarized in Table 4. The peak observed at 11.46 minutes ispossibly DAG dimer and the peak eluted at 22.6 minutes contributedmultiple peaks in LC-MS with m/z of 271, 357, 417, 512, and other peaks,which might be condensed products (FIG. 4). These data are consistentwith the impurity profile expected by previous studies. As expected, themonoepoxide and dulcitol are two major degradation products obtained bythis method.

TABLE 4 RT (min) % Area Base peak m/z* m/z Comments 4.55 1.22 [M + Na]⁺= 205.1 182 dulcitol 4.92 2.68 [M + Na]⁺ = 351.1 328 Mono-epoxide dimer187 Mono-epoxide Na adduct 5.21 2.31 [M + Na]⁺ = 187.1 164 Mono-epoxide6.81 91.35 [M + Na]⁺ = 169.1 146 DAG 11.46 0.22 [M + Na]⁺ = 289.1 266DAG dimer 22.61 2.22 271, 357, 417, 521 Condensed products

Example 3

HPLC Analysis with Formic Acid in Water/Methanol Gradient to ImproveResolution of Mono-Epoxide Peaks

To improve the resolution of mono-epoxide peaks, a new method wasdeveloped. This new method employed the following parameters: The columnwas Atlantis C18, 250×4.6 mm, 5 μm. The column temperature was 30° C.The flow rate was 0.5 mL/min. The injection volume was 100 μL. The ELSDdetector was operated in cooling mode with the drift tube temperature of35° C. and gain 400, 2 pps, 45 PSI. Mobile Phase A was 0.05% formic acidin water. Mobile Phase B was 100% methanol. The gradient was shown inTable 5:

TABLE 5 Time, min % A % B 0 100 0 25 90 10 25.1-35 10 90 35.1-50 100 0

Better resolution of the early eluting impurities has been observed(refer to chromatogram of DAG sample below in FIG. 5). Dulcitol labeledpeak 2 was eluted at retention time of 6.26 minutes or relativeretention time (RRT) of 0.59. Dianhydrogalactitol was eluted at 10.86minutes.

Since ELSD response is not linear, an external calibration standardcurve is required for a known impurity, such as dulcitol, to determinethe impurity content in a dianhydrogalactitol sample tested. For anunknown impurity contained in a sample of dianhydrogalactitol, theunknown impurity content can be estimated using a calibration standardcurve established by chromatography of dianhydrogalactitol referencematerial.

Example 4 Further Improved Method for Detection or Determination ofImpurities Employing Dual-Gradient HPLC Elution

A further improved analytical method for the detection or determinationof impurities in dianhydrogalactitol employs HPLC and ELSD withdual-gradient elution in HPLC. This method is described below.

In this analytical method, the following materials and equipment areused: an Atlantis C18, 250×4.6-mm, 5 μm HPLC column; a quaternary orbinary HPLC pump; an Evaporative Light Scattering Detector (ELSD); anintegrator or computer-based analytical system; a calibrated analyticalbalance; and Class A volumetric flasks and pipettes. The followingreagents and standards are used: a dulcitol reference standard asdescribed above; HPLC grade water; HPLC grade or equivalent formic acid(FA); HPLC grade or equivalent acetonitrile (ACN); and HPLC grade orequivalent methanol (MeOH).

For solutions that are employed in the method, the volume may be scaledto suit the needs of the analysis. It is important that all mobilephases are filtered. The sintered glass in the filtration apparatus maybe a source of buffers that may interfere with sensitivity in the ELSD.All filtration apparatus should be rinsed thoroughly with Milli-Q gradewater. To perform this, approximately 500 mL of Milli-Q grade water isfiltered through the filtration apparatus. The water is discarded andthe mobile phase is then filtered.

Test solution preparations are to be made in a fume hood usingappropriate PPE (gloves, lab coat, and safety glasses). Test solutionpreparations are to be stored in a fume hood for disposal and are to belabelled appropriately.

Mobile Phase A is prepared by pipetting 0.5 mL of formic acid into 1000mL of water and mixing well. The Mobile Phase A is filtered anddegassed.

Mobile Phase B is MeOH. The Mobile Phase B is filtered and degassed.

Diluent A is water. Diluent B is prepared by mixing 20 mL of ACN with180 mL of water and mixing well.

The standard and sample solution preparation is described below. Theblank solution is water. The dulcitol stock solution is prepared byaccurately transferring 100 mg of dulcitol reference standard to a 20-mLvolumetric flask. About 15 mL of Diluent B is added and sonicated todissolve. The solution is allowed to cool down to room temperature anddiluted to volume with Diluent B and mixed well (5 mg/mL). The followingstandard solutions are prepared: 0.2, 0.1, 0.08, 0.05, 0.03, 0.01 and0.005 mg/mL (system sensitivity solution). A 4.0% standard solution isprepared by pipetting 2.0 mL of dulcitol stock solution into a 50-mLvolumetric flask. The solution is diluted to volume with water and mixedwell (0.2 mg/mL). A 2.0% standard solution is prepared by pipetting 5.0mL of 4.0% standard solution into a 10-mL volumetric flask. The solutionis diluted to volume with water and mixed well (0.10 mg/mL). A 1.6%standard solution is prepared by pipetting 4.0 mL of 4.0% standardsolution into a 10-mL volumetric flask. The solution is diluted tovolume with water and mixed well (0.08 mg/mL). A 1.0% standard solutionis prepared by pipetting 2.5 mL of 4.0% standard solution into a 10-mLvolumetric flask. The solution is diluted to volume with water and mixedwell (0.05 mg/mL). An 0.60% standard solution is prepared by pipetting3.0 mL of 4.0% standard solution into a 20-mL volumetric flask. Thesolution is diluted to volume with water and mixed well (0.30 mg/mL). An0.20% standard solution is prepared by pipetting 1.0 mL of 4.0% standardsolution into a 20-mL volumetric flask. The solution is diluted tovolume with water and mixed well (0.01 mg/mL). An 0.10% standardsolution (system sensitivity solution) is prepared by pipetting 5.0 mLof 0.20% standard solution into a 10-mL volumetric flask. The solutionis diluted to volume with water and mixed well (0.005 mg/mL).

Test sample working solutions are to be prepared in duplicate (A and B).Sample solutions must be prepared just before analysis. Sampleinjections must be performed within 15 minutes of sample solutionpreparation. Sample dilution may be required, in some cases, toquantitate any impurities that are overloaded.

For sample preparation, approximately 50 mg of test sample is accuratelytransferred into a 10-mL volumetric flask. The test sample is dissolvedin water and diluted to volume and mixed well (5 mg/mL).

The HPLC operating conditions are as follows: The column is the AtlantisC18 250×4.6-mm, 5 μm HPLC column. Mobile Phase A is 0.05% FA in water.Mobile Phase B is MeOH. Gradients A and B are described below in Table6. The column temperature is 30° C. The sample temperature is 5° C. Theflow rate is 0.5 mL/min. The injection volume is 100 μL. The run time is50 minutes for Gradient A and 20 minutes for Gradient B.

TABLE 6 Time, mins % A % B Gradient A 0 100 0 25 90 10 25.1 10 90 35 1090 35.1 100 0 50 100 0 Gradient B 0 100 0 7.5 97 3 7.6 100 0 20 100 0

The ELSD operating conditions are as follows: The gain is 400. The drifttube temperature is 45° C. The gas pressure (nitrogen) is 35 PSI. Thenebulizer is set to cooling. The data rate is 2 points per second. TheRayleigh factor, set directly in the detector, is 6.0.

The injection sequence is shown in Table 7. Blank injections are to berepeated until a stable and reproducible baseline is obtained.

TABLE 7 Solution # of Injections Gradient Blank Solution  1* A 0.1%Standard Solution (System Sensitivity) 1 B 0.20% Standard Solution 5 B0.60% Standard Solution 1 B 1.0% Standard Solution 1 B 1.6% StandardSolution 1 B 2.0% Standard Solution 1 B 0.20% Standard Solution Check 1B Test Sample Solution Prep A 1 A Test Sample Solution Prep B 1 A 0.20%Standard Solution Check 1 B

Additional test sample injections may be added as required. No more than6 test sample solution injections are to be performed before repeatingthe 0.20% standard solution check injection.

For evaluation, all peaks should be integrated associated with anyunknown impurities detected. If baseline noise is an issue, make surethat the waste is properly drained from the detector. It may benecessary to check that there is no liquid accumulated inside the tubingdraining the waste from the ELSD. The tubing position should becorrected as needed. If the waste is being properly drained and thebaseline noise is an issue, the detector may be cleaned. If required,the following cleaning method may be used prior to analysis. Forcleaning, the HPLC conditions are as follows: The column is to beremoved from the instrument and a union is to be used. The mobile phaseis 100% H₂O (isocratic 100%). The flow rate is 1.0 mL per minute. Thecolumn temperature is ambient temperature. The run time is 60 minutes.The ELSD operating conditions are as follows: The gain is 50. The drifttube temperature is 100° C. The gas pressure (nitrogen) is 50 PSI. Thenebulizer is set to heating at 75%.

Typical retention times are shown in Table 8. In Table 8, “DAG” isdianhydrogalactitol. DAG in the test sample is not quantitated in thismethod. DAG is observed as a wide peak due to the concentration of DAGrequired. Retention time for DAG in sample solution is approximatelybetween 10 and 13 minutes.

TABLE 8 Component RT, min RRT Dulcitol 6.4 0.53 * DAG 12.1* 1.00

FIG. 6 is an example chromatogram of a blank solution.

FIG. 7 is an example chromatogram of 0.10% standard solution (systemsensitivity solution).

FIG. 8 is an example chromatogram of a test solution.

System suitability requirements are as follows. For blank solutioninjection, no interfering peaks should be observed at the retention timeof the dulcitol peak or of any known impurities. A stable andreproducible baseline should be observed; continue to inject the blanksolution until this condition is met. For system sensitivity, thedulcitol peak subsequent to the injection of the 0.10% standard solutionshould be observed. The signal-to-noise ratio for the dulcitol peakshould be reported. If contamination in the mobile phase is suspected(i.e., baseline noise is greater than 1.0 LSU) or the dulcitol peak isnot observed, the mobile phase should be re-prepared or the clean-upprocedure described above should be performed. The USP tailing factorfor the dulcitol peak for the first and last injections of the 0.20%standard solution is no more than 2.0. For precision, the % RSD for thelog of peak area in the five injections is calculated. The % RSD must beno more than 15%.

For calculations, all peaks that are not attributed to the blank shouldbe integrated. The logarithm of the response versus the logarithm of theconcentration for the 0.10% through the 2.0% standard solutions fordulcitol (including the 5 precision injections of the 0.20% standard) isplotted. The correlation coefficient (r) must be no less than 0.98 forthe linearity curve. The slope and intercept are determined from thecurve. The linearity curve for dulcitol is used to determine theconcentration in mg/mL of unknowns and dulcitol impurities in thesample.

For determination of individual unknown impurities in the sample, theslope and intercept from the linearity curve for dulcitol as describedabove are used. Using the Log [area response] of the Unknown, the Log[concentration] of the unknown is determined as follows using Equation(1):

$\begin{matrix}{{{Log}\left\lbrack {{Unknown}\mspace{14mu}{concentration}} \right\rbrack} = {\frac{{{Log}\left\lbrack {{Unknown}\mspace{14mu}{response}} \right\rbrack} - {Intercept}}{Slope}.}} & (1)\end{matrix}$

The amount of unknown impurity (in mg/mL) is determined as follows usingEquation (2):Unknown concentration (mg/mL)=10^(Log [Unknown concentration])  (2).

The percentage of each unknown impurity is determined as follows usingEquation (3):

$\begin{matrix}{{\%\mspace{14mu}{Unknown}} = {\frac{{Unknown}\mspace{14mu}{{concentration}\left( {{mg}\text{/}{mL}} \right)} \times 100}{{Spl}.\mspace{14mu}{Conc}.\;\left( {{mg}\text{/}{mL}} \right)}.}} & (3)\end{matrix}$

Alternatively, quantitation using dulcitol standards may be formed usinglog-log linear function in Empower (Waters Corp.)

Similar equations, specifically Equations (4)-(6), are used for thedetermination of the dulcitol impurity in the sample.

Using the log [area response] for dulcitol, the log [concentration] ofdulcitol is determined using Equation (4):

$\begin{matrix}{{{Log}\left\lbrack {{Dulcitol}\mspace{14mu}{concentration}} \right\rbrack} = {\frac{{{Log}\left\lbrack {{Dulcitol}\mspace{14mu}{response}} \right\rbrack} - {Intercept}}{Slope}.}} & (4)\end{matrix}$

The concentration of dulcitol impurity (in mg/mL) is determined usingEquation (5):Dulcitol concentration (mg/mL)=10^(Log [Dulcitol concentration])  (5).

The percentage of dulcitol impurity is determined using Equation (6):

$\begin{matrix}{{\%\mspace{14mu}{Dulcitol}} = {\frac{{Dulcitol}\mspace{14mu}{concentration}\;\left( {{mg}\text{/}{mL}} \right) \times 100}{{Spl}.\mspace{14mu}{Conc}.\left( {{mg}\text{/}{mL}} \right)}.}} & (3)\end{matrix}$

Advantages of the Invention

The present invention provides an improved analytical method for thedetection and quantitation of impurities present in dianhydrogalactitolpreparations, including dulcitol and unknown impurities, as well asmethods for isolation and identification of unknown impurities presentin dianhydrogalactitol preparations. The methods of the presentinvention allow the large-scale preparation of dianhydrogalactitol ofhigh purity suitable for pharmaceutical use and reduce the possibilityof significant side effects caused by the presence of impurities indianhydrogalactitol preparations intended for pharmaceutical use.

Methods according to the present invention possess industrialapplicability for analysis of dianhydrogalactitol preparations anddetermination and quantitation of impurities in dianhydrogalactitolpreparations.

With respect to ranges of values, the invention encompasses eachintervening value between the upper and lower limits of the range to atleast a tenth of the lower limit's unit, unless the context clearlyindicates otherwise. Moreover, the invention encompasses any otherstated intervening values and ranges including either or both of theupper and lower limits of the range, unless specifically excluded fromthe stated range.

Unless defined otherwise, the meanings of all technical and scientificterms used herein are those commonly understood by one of ordinary skillin the art to which this invention belongs. One of ordinary skill in theart will also appreciate that any methods and materials similar orequivalent to those described herein can also be used to practice ortest this invention.

The publications and patents discussed herein are provided solely fortheir disclosure prior to the filing date of the present application.Nothing herein is to be construed as an admission that the presentinvention is not entitled to antedate such publication by virtue ofprior invention. Further the dates of publication provided may bedifferent from the actual publication dates which may need to beindependently confirmed.

All the publications cited are incorporated herein by reference in theirentireties, including all published patents, patent applications, andliterature references, as well as those publications that have beenincorporated in those published documents. However, to the extent thatany publication incorporated herein by reference refers to informationto be published, applicants do not admit that any such informationpublished after the filing date of this application to be prior art.

As used in this specification and in the appended claims, the singularforms include the plural forms. For example the terms “a,” “an,” and“the” include plural references unless the content clearly dictatesotherwise. Additionally, the term “at least” preceding a series ofelements is to be understood as referring to every element in theseries. The inventions illustratively described herein can suitably bepracticed in the absence of any element or elements, limitation orlimitations, not specifically disclosed herein. Thus, for example, theterms “comprising,” “including,” “containing,” etc. shall be readexpansively and without limitation. Additionally, the terms andexpressions employed herein have been used as terms of description andnot of limitation, and there is no intention in the use of such termsand expressions of excluding any equivalents of the future shown anddescribed or any portion thereof, and it is recognized that variousmodifications are possible within the scope of the invention claimed.Thus, it should be understood that although the present invention hasbeen specifically disclosed by preferred embodiments and optionalfeatures, modification and variation of the inventions herein disclosedcan be resorted by those skilled in the art, and that such modificationsand variations are considered to be within the scope of the inventionsdisclosed herein. The inventions have been described broadly andgenerically herein. Each of the narrower species and subgenericgroupings falling within the scope of the generic disclosure also formpart of these inventions. This includes the generic description of eachinvention with a proviso or negative limitation removing any subjectmatter from the genus, regardless of whether or not the excisedmaterials specifically resided therein. In addition, where features oraspects of an invention are described in terms of the Markush group,those schooled in the art will recognize that the invention is alsothereby described in terms of any individual member or subgroup ofmembers of the Markush group. It is also to be understood that the abovedescription is intended to be illustrative and not restrictive. Manyembodiments will be apparent to those of in the art upon reviewing theabove description. The scope of the invention should therefore, bedetermined not with reference to the above description, but shouldinstead be determined with reference to the appended claims, along withthe full scope of equivalents to which such claims are entitled. Thoseskilled in the art will recognize, or will be able to ascertain using nomore than routine experimentation, many equivalents to the specificembodiments of the invention described. Such equivalents are intended tobe encompassed by the following claims.

What is claimed is:
 1. An analytical method for analyzing the presenceand quantity of impurities present in a preparation ofdianhydrogalactitol comprising the step of: analyzing a preparation ofdianhydrogalactitol by subjecting the preparation to high performanceliquid chromatography (HPLC) on an HPLC column using elution with amobile phase gradient to separate dianhydrogalactitol from dulcitol andother contaminants of the preparation, wherein the HPLC column is asilica gel column bonded to C 18 compounds and finished with anendcapping procedure employing Lewis acid-Lewis base chemistry, whereinthe mobile phase gradient comprises Mobile Phase A and Mobile Phase B,with Mobile Phase A being 0.05% formic acid in water and Mobile Phase Bbeing 100% methanol, wherein a first elution sequence is performed witha gradient of 95% water/5% acetonitrile to 70% water/30% acetonitrile,returning to 95% water/5% acetonitrile, wherein following the firstelution sequence, a second elution sequence is performed as follows:from 0 minutes to 7.5 minutes with 100% of 0.05% formic acid; from 7.5minutes to 7.6 minutes with 97% of 0.05% formic acid and 3% of methanol;and from 7.6 minutes to 20 minutes with 100% of 0.05% formic acid, andwherein the high performance liquid chromatography employs evaporativelight scattering detection (ELSD).
 2. The analytical method of claim 1wherein a time schedule for varying the first elution sequence is asfollows: 0 minutes, 95% water/5% acetonitrile; 15 minutes, 95% water/5%acetonitrile; 15.1 minutes, 70% water/30% acetonitrile; 20 minutes, 70%water/30% acetonitrile; 20.1 to 35 minutes, 95% water/5% acetonitrile.3. The analytical method of claim 1 wherein the method detects amonoepoxide degradation product of dianhydrogalactitol, a monoepoxidedimer, and dulcitol.
 4. The analytical method of claim 3 wherein themethod also detects a dimer of dianhydrogalactitol and condensedproducts.
 5. The analytical method of claim 1 wherein the peaksresulting from HPLC are analysed by LC-MS.
 6. The analytical method ofclaim 1 wherein the method further comprises a step of determining therelative concentration of one or more peaks resolved by high performanceliquid chromatography that represent compounds other thandianhydrogalactitol itself.
 7. The analytical method of claim 1 whereinthe column temperature is about 30° C.
 8. The analytical method of claim1 wherein the flow rate of the mobile phase gradient is about 0.5mL/min.
 9. The analytical method of claim 1 wherein the ELSD detector isoperated in cooling mode with the drift tube temperature of 35° C. andgain 400, 2 pps, 45 PSI.
 10. The analytical method of claim 1 whereinthe first elution sequence is performed from 0 minutes to 25 minuteswith 100% of 0.05% formic acid in water, from 25 minutes to 25.1 minuteswith 90% of 0.05% formic acid in water and 10% of 100% methanol, from25.1 minutes to 35 minutes with 10% of 0.05% formic acid in water and90% of 100% methanol, and from 35.1 minutes to 50 minutes with 100% of0.05% formic acid in water.
 11. The analytical method of claim 1 whereinthe method further comprises the preparation of an external calibrationstandard curve for an impurity.
 12. The analytical method of claim 10wherein the method further comprises the preparation of an externalcalibration standard curve for an impurity.
 13. The analytical method ofclaim 11 wherein the impurity is selected from the group consisting ofdulcitol, a monoepoxide degradation product of dianhydrogalactitol, anda dimer of dianhydrogalactitol.
 14. The analytical method of claim 12wherein the impurity is selected from the group consisting of dulcitol,a monoepoxide degradation product of dianhydrogalactitol, and a dimer ofdianhydrogalactitol.
 15. The analytical method of claim 1 wherein, foran unknown impurity, the content of the unknown impurity is estimatedusing a calibration standard curve established by chromatography ofdianhydrogalactitol reference material.
 16. The analytical method ofclaim 1 wherein, for an unknown impurity, the content of the unknownimpurity is estimated using a calibration standard curve established bychromatography of dianhydrogalactitol reference material.
 17. Theanalytical of claim 1 wherein the column temperature for HPLC is about30° C., the sample temperature for HPLC is about 5° C., the flow ratefor HPLC is about 0.5 mL/min, and the injection volume is about 10-100μL.
 18. The analytical method of claim 1 wherein, for ELSD, the gain isabout 400, the drift tube temperature is about 45° C., the gas pressureis about 35 PSI of nitrogen, the nebulizer is set to cooling, the datarate is 2 points per second, and the Rayleigh factor is about 6.0. 19.The analytical method of claim 1 wherein standards of 2.0% dulcitol,1.6% dulcitol, 1.0% dulcitol, 0.60% dulcitol, 0.20% dulcitol, and 0.10%dulcitol are employed to determine the sensitivity and linearity of thesystem.
 20. The analytical method of claim 1 wherein the retention timefor dulcitol is about 6.4 minutes and the retention time fordianhydrogalactitol is about 12.1 minutes.
 21. The analytical method ofclaim 1 wherein the amount and percentage of a dulcitol impurity aredetermined from the results of HPLC and ELSD.
 22. The analytical methodof claim 1 wherein the amount and percentage of an unknown impurityother than dulcitol are determined from the results of HPLC and ELSD.